Citi Upgrades FibroGen (FGEN) to Buy
Tweet
Share
E-mail
Get Alerts FGEN Hot Sheet
Price: $1.02 +4.08%
Rating Summary:
3 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
3 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Citi analyst Joel Beatty upgraded FibroGen (NASDAQ: FGEN) from Neutral to Buy with a price target of $71.00.
The analyst sees an opportunity following the recent pullback and head of Roxa Phase 3 data in the first half of 2019.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $38.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- MarineMax (HZO) PT Lowered to $35 at Stifel
- Merck (MRK) PT Raised to $143 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
